FDA Warning Letters · October 20, 2026 · Primary source
Olympus Medical Systems Corporation
Summary
FDA issued a warning letter dated October 7, 2026, to Olympus Medical Systems Corporation citing quality system regulation violations across six manufacturing facilities in Japan, Germany, and Minnesota, covering surgical and endotherapy devices including bronchoscopes, cystoscopes, sphincterotomes, hemostatic clips, and insufflators. Violations include failures of design validation, risk management documentation, and CAPA processes under 21 CFR Part 820, and are linked to multiple Class I recalls involving patient safety risks such as overpressure events, endobronchial combustion, and unintended vessel cutting. FDA found Olympus's responses to date inadequate because corrective actions remain incomplete and unverified.
What this may mean
Olympus faces potential import alerts, withholding of premarket approvals, and further regulatory action across six facilities if it does not resolve documented QSR violations. Hospitals and ASCs that use Olympus endoscopy and surgical equipment are directly affected by the Class I recalls identified in the letter, including the UHI-4 insufflator and BF-1TH190 bronchoscope. Facilities using these devices must verify recall compliance and assess whether distributed nonconforming devices remain in service.
Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.
Related items
- FDA Recalls · August 20, 2026Optimal Balance Pharmacy Issues Voluntary Nationwide Recall of Certain Lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials Due to Elevated Endotoxin LevelsScore 68
- FDA Warning Letters · October 14, 2026SCA Pharmaceuticals, LLCScore 50
- FDA Recalls · August 24, 2026Vitruvias Therapeutics, Inc Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super PotencyScore 50
- FDA Recalls · August 28, 2026B. Braun Medical Inc. Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container Due to the Presence of Particulate MatterScore 48
- FDA Warning Letters · October 20, 2026Signature Formulations LLCScore 46
- FDA Warning Letters · October 7, 2026Amazon.com, Inc.Score 46